SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced positive topline results from its Phase 1 clinical trial of ...

Daré Bioscience Inc (NASDAQ: DARE) has announced positive topline results from its Phase 1 trial of DARE-HRT1 as part of a hormone therapy (HT) regimen to treat the vasomotor symptoms (VMS) and ...

Croatian public broadcaster HRT1 has extended its remake of Skam following a stellar first series, Broadcast International has learned. The show, sold via German distributor Beta Film, is known ...

SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the initiation of a Phase 1 clinical trial of DARE-HRT1.

Please provide your email address to receive an email when new articles are posted on . Intravaginal ring that contains estradiol and progesterone reduced vaginal pH and percentage of parabasal cells.

Johnson reiterated the targeted Q4 2025 launch for DARE to PLAY Sildenafil cream through a 503B outsourcing facility. She stated, "We remain on track to support a fourth quarter 2025 launch." ...

Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly ...

The First Clinical Study Using the Novel Segmented Intravaginal Ring (IVR) Technology Validates its Potential to Provide a Versatile Convenient Drug Delivery Solution SAN DIEGO, June 28, 2021 (GLOBE ...

DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring delivering both estrogen and progestogen hormone therapy SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience ...